Abstract
Prolyl oligopeptidase (PO) interacts with α-synuclein in vitro. It is a weak interaction that induces a nucleation prone conformation of α-synuclein. PO accelerates aggregation and fibril formation of α-synuclein in a process that can be reversed by specific inhibitors and is also influenced by an impairing mutation in the PO active site. There is evidence that PO and α-synuclein also interact intracellularly, especially in conditions where the expression of α-synuclein is high. Specific PO inhibitors reduce the number of cells with α-synuclein inclusions in a cellular model of Parkinsons disease. If these interactions also exist in the human brain, PO may be a target for the treatment of Parkinsons disease and other synucleinopathies. Whether PO also contributes to the normal physiological functions of α-synuclein remains an open question, but there are some intriguing parallels between the proposed functions of both proteins that deserve further investigation.
Keywords: Amyloid, peptidase, neurodegeneration, neurotransmission, Parkinson's disease, prolyl oligopeptidase, synuclein, Synucleinopathies, Multiple system atrophy, Dictyostelium discoidum, Alzheimers disease, Z-pro-prolinal, UAMC-00021, Tubulin
CNS & Neurological Disorders - Drug Targets
Title: Interaction of Prolyl Oligopeptidase with α-Synuclein
Volume: 10 Issue: 3
Author(s): Anne-Marie Lambeir
Affiliation:
Keywords: Amyloid, peptidase, neurodegeneration, neurotransmission, Parkinson's disease, prolyl oligopeptidase, synuclein, Synucleinopathies, Multiple system atrophy, Dictyostelium discoidum, Alzheimers disease, Z-pro-prolinal, UAMC-00021, Tubulin
Abstract: Prolyl oligopeptidase (PO) interacts with α-synuclein in vitro. It is a weak interaction that induces a nucleation prone conformation of α-synuclein. PO accelerates aggregation and fibril formation of α-synuclein in a process that can be reversed by specific inhibitors and is also influenced by an impairing mutation in the PO active site. There is evidence that PO and α-synuclein also interact intracellularly, especially in conditions where the expression of α-synuclein is high. Specific PO inhibitors reduce the number of cells with α-synuclein inclusions in a cellular model of Parkinsons disease. If these interactions also exist in the human brain, PO may be a target for the treatment of Parkinsons disease and other synucleinopathies. Whether PO also contributes to the normal physiological functions of α-synuclein remains an open question, but there are some intriguing parallels between the proposed functions of both proteins that deserve further investigation.
Export Options
About this article
Cite this article as:
Lambeir Anne-Marie, Interaction of Prolyl Oligopeptidase with α-Synuclein, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653878
DOI https://dx.doi.org/10.2174/187152711794653878 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets A Closer Look at α-Secretase
Current Alzheimer Research Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Current Alzheimer Research In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Osteopontin as a Potential Therapeutic Target for Ischemic Stroke
Current Drug Delivery Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas
Current Cancer Drug Targets Mesenchymal stem cell therapy for inflammatory bowel diseases: promise and challenge
Current Stem Cell Research & Therapy Traditional Uses, Phytochemistry, Pharmacology and Anticancer Activity of Açaí (Euterpe oleracea Mart): A Narrative Review
Current Traditional Medicine Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Current Medicinal Chemistry Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Myc Decoy Oligodeoxynucleotide Inhibits Growth and Modulates Differentiation of Mouse Embryonic Stem Cells as a Model of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future
Current HIV Research Cytotoxic, Antiproliferative and Apoptotic Effects of New Benzimidazole Derivatives on A549 Lung Carcinoma and C6 Glioma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets